Application
|
Acute administration of Galantamine (0.3-3 mg/kg, i.p.) increased IGF2 mRNA levels in time- and dose-dependent manner. Galantamine (3 mg/kg, i.p.) increased fibroblast growth factor 2 mRNA levels and decreased brain-derived neurotrophic factor mRNA levels in the hippocampus. Galantamine increased hippocampal IGF2 protein.
|
References:
[1]. Thomsen T, Kaden B, Fischer J P, et al. Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galanthamine, physostigmine and tacrine[J]. Clinical Chemistry and Laboratory Medicine, 1991, 29(8): 487-492.
[2]. Pereira E F, Alkondon M, Reinhardt S, et al. Physostigmine and galanthamine: probes for a novel binding site on the alpha 4 beta 2 subtype of neuronal nicotinic acetylcholine receptors stably expressed in fibroblast cells[J]. Journal of Pharmacology and Experimental Therapeutics, 1994, 270(2): 768-778.
[3]. Storch A, Schrattenholz A, Cooper J C, et al. Physostigmine, galanthamine and codeine act as ‘noncompetitive nicotinic receptor agonists’ on clonal rat pheochromocytoma cells[J]. European Journal of Pharmacology: Molecular Pharmacology, 1995, 290(3): 207-219.
[4]. Kita Y, Ago Y, Takano E, et al. Galantamine increases hippocampal insulin-like growth factor 2 expression via α7 nicotinic acetylcholine receptors in mice[J]. Psychopharmacology, 2013, 225(3): 543-551.
|